Double Marker vs. Triple Marker Test: Differences, Timing, Results & How They Work Together 

Introduction

The pregnancy period involves several checkups, which are essential to ensure that the baby is growing well and staying healthy. An important part of these check-ups is early pregnancy (prenatal) screening, which helps doctors understand if there are any chances of certain health conditions in the baby early on. These are simple screening tests, which are different from diagnostic procedures¹. 

A type of screening tests employed for this purpose are the marker tests. These are the blood tests which measure some natural components (biomarkers) in the mother’s blood. The levels of these markers can give an idea about the baby’s risk of conditions, for e.g., some genetic conditions like Down’s syndrome².

These marker tests include the double marker test and the triple marker test. They are similar but done at different stages of pregnancy and check different types of markers^3,4.

In this article, we’ll explain the difference between double marker and triple marker tests, when they are performed, what their results say, and how they can be employed together to assess the baby’s health. 

What Is a Double Marker Test?

The double marker test is a pregnancy screening blood test, which helps assess the risk of certain genetic conditions in the baby during early pregnancy. It is usually performed as a part of first-trimester (first 3 months of pregnancy) screening, which helps determine early indications of whether further detailed testing may be needed³.

The test measures two specific markers present in the mother’s blood: 

• Free β-human chorionic gonadotrophin (free β-hCG): A hormone produced during pregnancy and is important for supporting pregnancy 
• Pregnancy-associated plasma protein A (PAPP-A): A protein produced by the placenta (tissue that attaches baby to the mother) and uterus lining, linked to the growth of the baby 

The result of these markers may help evaluate the placental and baby’s health (abnormal levels of markers may indicate poor or abnormal formation of the placenta)⁵. This result is then combined with ultrasound scanning tests (especially nuchal translucency (NT)) and the mother’s age to estimate the possible risk³. 

This test is usually performed between the 10^th and 13^th weeks +6 days of gestation (pregnancy)⁶. Abnormal levels (too high or too low) may help indicate increased risk of conditions like: 

• Down Syndrome: (Trisomy 21-A genetic defect caused by an extra copy of chromosome 21) Associated with high β-hCG and low PAPP-A 
• Edwards Syndrome: (Trisomy 18- A genetic defect caused by an extra copy of chromosome 18) Associated with low β-hCG and low PAPP-A³ 

However, for confirmation, the doctors might prescribe several other diagnostic tests. 

What Is a Triple Marker Test?

A triple market test is also a pregnancy screening test, but it is usually performed during the second trimester (4^th– 6^th month) of pregnancy. This test helps assess the risk of several genetic disorders in the baby, by evaluating certain markers in the mother’s blood, along with the mother’s age, during the pregnancy periods. This, in turn, helps evaluate whether further detailed diagnostic testing for specific conditions may be needed or not^2,7. 

The test measures three specific markers present in the mother’s blood: 

• Alpha Fetoprotein (AFP): A protein made by the baby’s liver^4,8 
• Human Chorionic Gonadotrophin (hCG): A hormone produced during pregnancy^3,4.
• Unconjugated Oestriol (uE3): A form of estrogen produced by the placenta and may indicate the health of a developing baby^4,9 

The test is usually performed between 15 and 22 weeks of gestation⁶. It may help assess the risk of chromosomal conditions like: 

• Neural Tube Defects (early baby’s brain and spine defects): Only dependent to AFP. Associated with abnormal levels (too low or too high of AFP)⁸ 
• Down’s Syndrome: Associated with low uE3, high β-hCG and low AFP 
• Edwards’s Syndrome: Associated low uE3 low β-hCG and low AFP⁶ 

Note that abnormal levels are just the indicators of a higher risk for these conditions and not confirmatory⁷. The doctor might recommend other diagnostic tests for further evaluation if needed. 

Apart from triple marker test, second trimester screening also involves a detailed targeted ultrasound scan, also called as level II anomaly scan, which helps evaluate any structural abnormalities in the baby. This is usually performed between 18 and 22 weeks of pregnancy. It helps in assessing baby’s heart, brain, limbs, placental location, amniotic fluid level, etc¹⁰.

Difference Between Double Marker and Triple Marker Test

The following is a table which shows the difference between the double marker and triple marker tests: 

 How Do These Tests Work Together?

The double marker and triple marker tests are not competing tests; they are often performed during different stages of pregnancy to assess the baby’s health. The double marker test is performed during the first trimester, while the triple marker is performed during the second trimester^3,6,7. 

The double marker test primarily assesses the risks of genetic conditions. Since it is done early, it helps doctors decide sooner if any additional or more detailed tests are needed. The triple marker acts as a follow-up screening test, especially when the first-trimester screening test was missed, if the results during the double marker test showed high risk or any additional assessment is required, or if the doctor wants a broader evaluation, including neural tube defects. 

If the double marker test performed shows low risks, no further marker testing may be advised by the doctor. If the double marker was missed, the triple marker test becomes an important alternative. In some cases, the triple marker test may be used as an additional screening tool depending on clinical need. However, combining screening tests from the first and second trimesters is said to improve the chances of detecting problems compared to doing just one test⁶.

When to Take These Tests?

There is a difference between double marker and triple marker tests in their timeline. 

• Double Marker Test: Usually performed during the first trimester of pregnancy, between 10 and 13 weeks, 6 days of gestation, ideally along with NT scan⁶. During this period the levels of β-hCG and PAPP-A may be more accurate in detecting risk of chromosomal conditions. The baby is at an early stage, so the doctors still have time to do confirmatory tests early³. 
• Triple Marker Test: Usually performed during the second trimester of pregnancy, between 15 and 22 weeks of gestation^4,6. This test is important because it may help assess the risk if the marker test was missed or they had shown high risk during the first trimester test⁶. 

How Are These Tests Done?

Both the double marker and triple marker tests are very simple tests which are performed during pregnancy. These are: 

• Simple Blood Tests: A small amount of blood may be collected from the mother using a needle⁶. The sample is then analysed in a laboratory to measure specific markers. 
• Needs No Major Preparation: Usually may not need any fasting or any special preparation. Blood tests during pregnancy testing generally may not require any kind of preparation before sample collection¹¹.
• Non-Invasive and Safe: Since the process involves only blood sample collection, it may be referred to as non-invasive³, as it causes no harm to the baby and mother¹¹. They are generally safe and commonly performed as part of pregnancy care. 

Who Should Take These Tests?

The double marker and triple marker tests are recommended to be performed by women coming under the following category: 

1. All Pregnant Women 

These tests are generally offered to all pregnant women as part of routine pregnancy care. (Triple marker may be considered less routine if double marker test is performed in the first trimester). They are mainly performed during the early stages of pregnancy. 

2. High-Risk Groups

These tests are especially important for women with higher chances of chromosomal abnormalities. 

• Aged 35 or older during pregnancy³ 
• Previous pregnancy with abnormalities 
• Family history of genetic birth defects⁶ 
• Abnormal scanning result 

Advantages of Double Marker and Triple Marker Tests

The following are some advantages of double marker and triple marker tests: 

• Early Risk Detection: Help identify the risks of genetic disorders in the first trimester, allowing timely monitoring and planning. Provides additional assessment in the second trimester⁶.
• Non-Invasive: Both tests involve only a simple blood sample from the mother, making them safe for both the mother and the baby^3,11. There is no direct contact with the baby, which makes these tests risk-free. 
• Helps in Decision Making: The results of these tests help doctors decide whether more definitive diagnostic tests, such as amniocentesis or chorionic villus sampling^4,6, are needed. This might make sure that only those pregnancies with high risks are subjected to further testing. 
• Better Overall Pregnancy Monitoring: When used together at different stages, these tests provide a more complete view of the baby’s health, helping track any potential concerns over time rather than relying on a single test⁶.
• Widely Available and Convenient: These tests are commonly performed in most labs and hospitals, making them easily accessible and convenient to include as part of routine pregnancy care. 

Limitations of Double and Triple Marker Tests

The following says some limitations of maker tests: 

• Non-Diagnostic: These are just screening tests, which means they only estimate the chance or risk of certain conditions. They cannot confirm whether the baby actually has a genetic condition or birth defect. Even if a high risk is estimated, further diagnosis is required for confirmation².
• False Positives/Negatives Possible: The results are based on probability, so they are not 100% accurate. Sometimes, the test may show a high risk even when the baby is healthy (false positive)², which can cause unnecessary worry. In other cases, it may show low risk even if a condition is present (false negative), meaning some cases can be missed. 
• May Need Further Testing: If the results indicate an increased risk, doctors usually recommend more accurate diagnostic tests, such as amniocentesis or chorionic villus sampling to confirm the diagnosis^2,6.
• Results can be Influenced by Other Factors: Factors like the mother’s age, weight, medical history, or incorrect pregnancy dating can sometimes affect the results, which is why these tests are always interpreted along with other clinical findings^3,6.

Safety and Risks of Double Marker and Triple Marker Tests

These marker tests are considered to be safe as they are non-invasive, since no complex cuts or breaks are made for screening. Hence, they have very limited risks. Risks may be there during sample collection only, which will not affect the baby. Even for the mother, these tests cause very minor side effects during blood collection like discomfort, pain or bruise at the injection site after blood collection, which usually subside soon after^6,11.

Conclusion

The double and triple marker tests are simple blood tests done during pregnancy to assess the risk of certain genetic conditions in the developing baby. Doing them at the right time is important for better accuracy. However, it is important to remember that these are just screening tests and not confirmatory tests, and abnormal results do not always mean that there’s an issue with the baby. Always consult your doctor to properly understand the results and decide the next steps if needed. 

Frequently Asked Questions (FAQs)

References

1. NHS. Screening tests in pregnancy [Internet]. National Health Service; [cited 2026 Apr 14]. Available from: https://www.nhs.uk/pregnancy/your-pregnancy-care/screening-tests/ 

2. Maternal Serum Marker Screening. Available from: https://www.ncbi.nlm.nih.gov/books/NBK132135/ 

3. Shiefa S, Amargandhi M, Bhupendra J, Moulali S, Kristine T. First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome. Ind J Clin Biochem. 2013;28(1):3-12. doi:10.1007/s12291-012-0269-9. Available from: https://pubmed.ncbi.nlm.nih.gov/24381414/

4. Triple-marker test as screening for Down syndrome: a meta-analysis. 1998. Available from: https://www.ncbi.nlm.nih.gov/books/NBK67524/ 

5. Ghasemi-Tehrani H, Sadeghian A, Entezari R. Relationship Between Pregnancy Complications and Serum Pregnancy Associated-Plasma-Protein-A and Free-β-Human Chorionic Gonadotropin in the First Trimester Among Iranian Women. J Family Reprod Health. 2017;11(4):219-224. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6168753/

6. Maines J, Langaker MD. Prenatal Genetic Screening. 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557702/ 

7. Vranken G, Reynolds T, Van Nueten J. Medians for second-trimester maternal serum markers: geographical differences and variation caused by median multiples-of-median equations. J Clin Pathol. 2006;59(6):639-644. doi:10.1136/jcp.2005.034272. Available from: https://pubmed.ncbi.nlm.nih.gov/16731605/

8. Alpha-Fetoprotein (AFP) Test. 2024. Available from: https://medlineplus.gov/lab-tests/alpha-fetoprotein-afp-test/ 

9. Estriol (Maternal Serum). Available from: https://www.gov.nl.ca/labformulary/formulary/estriol-maternal-serum/ 

10. Park SY, Jang IA, Lee MA, Kim YJ, Chun SH, Park MH. Screening for chromosomal abnormalities using combined test in the first trimester of pregnancy. Obstet Gynecol Sci. 2016;59(5):357. doi:10.5468/ogs.2016.59.5.357. Available from: https://pubmed.ncbi.nlm.nih.gov/27668198/

11. Prenatal Panel. 2024. Available from: https://medlineplus.gov/lab-tests/prenatal-panel/ 

12. What is noninvasive prenatal testing (NIPT) and what disorders can it screen for? 2021. Available from: https://medlineplus.gov/genetics/understanding/testing/nipt/ 

13. Carbone L, Cariati F, Sarno L, et al. Non-Invasive Prenatal Testing: Current Perspectives and Future Challenges. Genes. 2020;12(1):15. doi:10.3390/genes12010015. Available from: https://pubmed.ncbi.nlm.nih.gov/33374411/

Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof. 

Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.